Using trg- Strains of Salmonella typhimurium as Targeted Bacterial Therapies
Motile, nonpathogenic bacteria have the potential to overcome multidrug resistance because they can penetrate deeper than passively diffusing drug molecules. Controlling where bacteria accumulate in tumors is the critical step that will make them effective therapies for solid tumor cancers. Dr. Forbes and his co-investigator have discovered that unlike the wild-type strain of S. typhimurium, which accumulates in tumor necrosis, a trg knockout strain of S. typhimurium lacking the ribose/galactose receptor gene specifically accumulates in quiescent regions of tumors and induces apoptosis (programmed cell death). This tumor-targeting technology uses ribose/galactose receptor knockouts (trg- strains) of S. typhimurium to specifically target quiescent regions of tumors inaccessible to standard chemotherapeutics, thus providing a novel strategy for eradicating the primary causes of mortality from cancer: metastases and local recurrence.
- Treatment of solid tumor cancers such as lung, colon, liver, kidney, prostate, breast, pancreatic, ovarian, bladder, kidney, thyroid and skin cancers
- Nonpathogenic trg- strains of S. typhimurium as monotherapy or in combination with other cancer therapies such as chemotherapy, radiation therapy, immunotherapy, gene therapy, and cancer vaccines
- Targeted delivery of anticancer agents to tumor quiescence
- Ability of S. typhimurium to migrate specifically toward tumors and accumulate preferentially within tumors compared to normal tissue
- Ability of trg- strains of S. typhimurium to penetrate deeper into tumors than passively diffusing chemotherapeutics
- Ability of trg- strains of S. typhimurium to specifically target tumor quiescence rather than necrosis
- Intratumoral injection not required
US Patent 7,998,461 issued
Ling X. Shen, Ph.D., M.B.A.
Senior Licensing Officer
Commercial Ventures and Intellectual Property